reports
Zealand Pharma to participate in upcoming investor conferences in Sept...
Zealand Pharma to participate in upcoming investor conferences in September 2025 Press release – No. 12 / 2025 Zealand Pharma to participate in upcoming investor conferences in September 2025 Copenhagen, Denmark, August 28, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company will participate in the following investor conferences in September 2025. Jefferies Swiss Healthcare Summit 2025, September 3 in Zürich Adam Lange, Vice President, Investo...
Zealand Pharma major shareholder announcement: Van Herk Investments B....
Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Company announcement – No. 19 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, August 20, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 20 August 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 19 August 2025, Van Herk Investments B.V. (Du...
- Jacob Mekhael
Zealand Pharma 2Q25 results confirm timelines, upcoming CMD in Decembe...
Zealand's 2Q25 results hold no surprises, and show that the company is on track operationally with pipeline timelines being reiterated. While no big data readouts are expected for the remainder of the year, the company is gearing up for a news heavy 1H26 and we most look forward to phase 2b results with petrelintide (amylin analog, partnered with Roche). Zealand reported a cash position of DKK 16,578m, and expects an additional $ 250m in anniversary payments under the Roche agreement in addition...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Wim Lewi
Zealand Pharma Announces Financial Results for the First Half of 2025
Zealand Pharma Announces Financial Results for the First Half of 2025 Company announcement – No. 18 / 2025 Zealand Pharma Announces Financial Results for the First Half of 2025Petrelintide collaboration with Roche off to a strong start, while key leadership appointments and solid financial position enable exciting next chapter for Zealand Pharma. Collaboration and license agreement with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management off to a strong start, with further insight and updates expected at Roche’s Pharma Day in Septe...
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to pre...
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results Press Release – No. 11 / 2025 Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results Copenhagen, Denmark, August 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 14, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financia...
Zealand Pharma major shareholder announcement: Van Herk Investments B....
Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Company announcement – No. 17 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, July 18, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 18 July 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 17 July 2025, Van Herk Investments B.V. (Dutch re...
Total number of shares and voting rights in Zealand Pharma as of June ...
Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Company announcement – No. 16 / 2025 Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Copenhagen, Denmark, June 30, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar mo...
- Jacob Mekhael
ADA amylin monotherapy highlights Zealand, Novo, Lilly
The American Diabetes Association (ADA) conference was held 20-23 June, 2025 and contained a number of highly anticipated updates in the obesity pipeline. We summarise the key amylin monotherapy datasets in this note including data from Zealand from petrelintide's phase 1b showing higher weight loss in females, Lilly's eloralintide full presentation, which shows that the higher doses which showed competitive weight loss and generated excitement following the abstract release also come with heada...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Thomas Couvreur
- Jacob Mekhael
Zealand Pharma We think sell off is overdone, jury is still out on elo...
Following the release of phase 1 MAD results for eloralintide (Lilly, no coverage) showing 11.3% weight loss at 12 weeks, Zealand's stock has declined -18% over the last 5 days. While the results look competitive vs. Zealand's petrelintide at first glance, key details on dosing and GI side effects per treatment arm remain undisclosed. We note that, given their similar activity on both amylin and calcitonin receptors, cagrilintide's long term 68 week data de-risks petrelintide's development. This...
- Jacob Mekhael
Zealand Pharma Dapiglutide phase 1b shows strong weight loss, plans to...
Zealand announced topline results from part 2 of the phase 1b multiple ascending dose (MAD) trial of dapiglutide (long-acting GLP-1/GLP-2 receptor dual agonist) in overweight/obese participants, which showed 11.4% (placebo adjusted) weight loss, coming in higher than semaglutide, and closer to tirzepatide at a similar timepoint in the phase 3 (STEP-1 and SURMOUNT-1) trials. By targeting GLP-2 on top of GLP-1, dapiglutide aims to address low grade inflammation on top of weight loss. As such, we b...
- Hilde Van Boxstael
- Jacob Mekhael
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Zealand Pharma announces positive topline results from 28-week Phase 1...
Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Company announcement – No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a mean of 11.6% after 28 weeks with dapiglutide escalated up to 26 mg, with 95% of trial participants being male, a median baseline BMI of 28.5 kg/m2, and no lifestyle modificationsTreatment with dapiglutide was assessed to be safe and well-tolerated with gastrointestinal a...
Zealand Pharma increases its share capital as a result of the exercise...
Zealand Pharma increases its share capital as a result of the exercise of employee warrants Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 292,508 divided into 292,508 new shares with a nominal value ...
- Jacob Mekhael
Zealand Pharma FIRST LOOK: Submits glepaglutide MAA to the EMA in shor...
Zealand announced the submission of a marketing authorization application (MAA) to the European Medicines Agency (EMA) for glepaglutide twice weekly (long-acting GLP-2 analog) in adults with short bowel syndrome (SBS). Looking ahead, we look forward to the initiation of the confirmatory phase 3 trial in the US, expected in 2H25. Beyond glepaglutide, which represents a small fraction of our SOTP, additional phase 1b data (higher dosing and longer treatment) for dapiglutide (long acting GLP-1/GLP-...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Wim Lewi
Zealand Pharma submits Marketing Authorization Application to the Euro...
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Press release – No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Copenhagen, Denmark, June 2, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the submission of a Marketing Authorization Application (MAA) to the European...
Transactions in Zealand Pharma shares and/or related securities by per...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 13 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, May 27, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received infor...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.